PALO ALTO, Calif., June 5 /PRNewswire-FirstCall/ -- Telik, Inc. announced that company management will provide a corporate overview at the Seventh Annual Needham & Company Biotechnology and Medical Technology Conference in New York City on Wednesday, June 11, 2008 at 10:00 a.m. Eastern time (7:00 a.m. Pacific time). A live and archived webcast of the presentation will be available on the Telik website, http://www.telik.com.
Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates.
CONTACT: Patricia P. Frias, Corporate Communications of Telik, Inc.,
+1-650-845-7927, pfrias@telik.com
Web site: http://www.telik.com//
